LGND
insider transactionsLIGAND PHARMACEUTICALS INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-18.2K
0 buy · 18.2K sell
Net value · 30d
-$4.5M
$0 in · $4.5M out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
14
0 buy · 18.2K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Director
$0
2.1K sh
Own New
-
Sell·S
Director
$544.8K
2.1K sh · $254.00
Own -6%
-
Exercise·M
Director
$141.8K
2.1K sh · $66.13
Own +6%
-
Exercise·M
Director
$0
1.0K sh
Own +19%
-
Exercise·M
Director
$0
3.0K sh
Own +72%
-
Sell·S
Director
$886.3K
3.5K sh · $256.08
Own -41%
-
Sell·S
Director
$765.0K
3.0K sh · $255.01
Own -26%
-
Exercise·M
Director
$51.6K
1.0K sh · $51.56
Own +10%
-
Exercise·M
Director
$154.7K
3.0K sh · $51.56
Own +40%
-
Sell·S
Director
$856.8K
3.4K sh · $251.62
Own -11%
-
Sell·S
Director
$173.9K
697 sh · $249.53
Own -2%
-
Sell·S
Director
$57.6K
232 sh · $248.11
Own -1%
-
Sell·S
Director
$63.5K
257 sh · $247.22
Own -1%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Other·F
Director
$43.1K
182 sh · $237.00
Own -3%
-
Grant·A
Director
$0
836 sh
Own +19%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Grant·A
Director
$0
836 sh
Own +3%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Grant·A
Director
$0
836 sh
Own +3%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Grant·A
Director
$0
836 sh
Own +2%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Grant·A
Director
$0
836 sh
Own +13%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Grant·A
Director
$0
836 sh
Own +10%
-
Exercise·M
CLO & Secretary · 10b5-1
$0
5.0K sh
Own +15%
-
Sell·S
CLO & Secretary · 10b5-1
$46.1K
200 sh · $230.41
Own -0%
-
Sell·S
CLO & Secretary · 10b5-1
$279.0K
1.2K sh · $229.47
Own -3%
-
Sell·S
CLO & Secretary · 10b5-1
$133.5K
584 sh · $228.57
Own -1%
-
Sell·S
CLO & Secretary · 10b5-1
$90.7K
400 sh · $226.78
Own -1%
-
Sell·S
CLO & Secretary · 10b5-1
$323.6K
1.4K sh · $225.97
Own -3%
-
Sell·S
CLO & Secretary · 10b5-1
$152.5K
677 sh · $225.20
Own -1%
-
Sell·S
CLO & Secretary · 10b5-1
$110.0K
491 sh · $223.95
Own -1%
-
Exercise·M
CLO & Secretary · 10b5-1
$261.4K
5.0K sh · $52.27
Own +12%
-
Exercise·M
Octavio Espinoza KEY
Chief Financial Officer
$0
764 sh
Own +5%
-
Exercise·M
Octavio Espinoza KEY
Chief Financial Officer
$0
972 sh
Own New
-
Exercise·M
Octavio Espinoza KEY
Chief Financial Officer
$51.4K
972 sh · $52.84
Own +4%
-
Exercise·M
Octavio Espinoza KEY
Chief Financial Officer
$48.6K
764 sh · $63.62
Own +3%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Stephen L Sabba | Exercise M | 2.1K | $0 |
| Jun 16, 2026 | Stephen L Sabba | Sell S | 2.1K | $544.8K |
| Jun 16, 2026 | Stephen L Sabba | Exercise M | 2.1K | $141.8K |
| Jun 12, 2026 | Jason Haas | Exercise M | 1.0K | $0 |
| Jun 12, 2026 | Jason Haas | Exercise M | 3.0K | $0 |
| Jun 12, 2026 | Jason Haas | Sell S | 3.5K | $886.3K |
| Jun 12, 2026 | Jason Haas | Sell S | 3.0K | $765.0K |
| Jun 12, 2026 | Jason Haas | Exercise M | 1.0K | $51.6K |
| Jun 12, 2026 | Jason Haas | Exercise M | 3.0K | $154.7K |
| Jun 10, 2026 | John L Lamattina | Sell S | 3.4K | $856.8K |
| Jun 10, 2026 | John L Lamattina | Sell S | 697 | $173.9K |
| Jun 10, 2026 | John L Lamattina | Sell S | 232 | $57.6K |
| Jun 10, 2026 | John L Lamattina | Sell S | 257 | $63.5K |
| Jun 5, 2026 | Martine Zimmermann | Grant A | 2.9K | $0 |
| Jun 5, 2026 | Martine Zimmermann | Other F | 182 | $43.1K |
| Jun 5, 2026 | Martine Zimmermann | Grant A | 836 | $0 |
| Jun 5, 2026 | Stephen L Sabba | Grant A | 2.9K | $0 |
| Jun 5, 2026 | Stephen L Sabba | Grant A | 836 | $0 |
| Jun 5, 2026 | John L Lamattina | Grant A | 2.9K | $0 |
| Jun 5, 2026 | John L Lamattina | Grant A | 836 | $0 |
| Jun 5, 2026 | John W Kozarich | Grant A | 2.9K | $0 |
| Jun 5, 2026 | John W Kozarich | Grant A | 836 | $0 |
| Jun 5, 2026 | Jason Haas | Grant A | 2.9K | $0 |
| Jun 5, 2026 | Jason Haas | Grant A | 836 | $0 |
| Jun 5, 2026 | Nancy Ryan Gray | Grant A | 2.9K | $0 |
| Jun 5, 2026 | Nancy Ryan Gray | Grant A | 836 | $0 |
| Jun 1, 2026 | Andrew Reardon 10b5-1 | Exercise M | 5.0K | $0 |
| Jun 1, 2026 | Andrew Reardon 10b5-1 | Sell S | 200 | $46.1K |
| Jun 1, 2026 | Andrew Reardon 10b5-1 | Sell S | 1.2K | $279.0K |
| Jun 1, 2026 | Andrew Reardon 10b5-1 | Sell S | 584 | $133.5K |
| Jun 1, 2026 | Andrew Reardon 10b5-1 | Sell S | 400 | $90.7K |
| Jun 1, 2026 | Andrew Reardon 10b5-1 | Sell S | 1.4K | $323.6K |
| Jun 1, 2026 | Andrew Reardon 10b5-1 | Sell S | 677 | $152.5K |
| Jun 1, 2026 | Andrew Reardon 10b5-1 | Sell S | 491 | $110.0K |
| Jun 1, 2026 | Andrew Reardon 10b5-1 | Exercise M | 5.0K | $261.4K |
| May 27, 2026 | Octavio Espinoza KEY | Exercise M | 764 | $0 |
| May 27, 2026 | Octavio Espinoza KEY | Exercise M | 972 | $0 |
| May 27, 2026 | Octavio Espinoza KEY | Exercise M | 972 | $51.4K |
| May 27, 2026 | Octavio Espinoza KEY | Exercise M | 764 | $48.6K |
About LGND insider trading
This page tracks insider transactions for LIGAND PHARMACEUTICALS INC (LGND) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.